South Korea
· Delayed Price · Currency is KRW KOREA PHARMA Statistics
Total Valuation
KOREA PHARMA has a market cap or net worth of KRW 166.76 billion. The enterprise value is 150.85 billion.
| Market Cap | 166.76B |
| Enterprise Value | 150.85B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 11.10% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | +11.10% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 64.77% |
| Owned by Institutions (%) | 0.11% |
| Float | 3.84M |
Valuation Ratios
The trailing PE ratio is 55.52.
| PE Ratio | 55.52 |
| Forward PE | n/a |
| PS Ratio | 2.09 |
| PB Ratio | 2.32 |
| P/TBV Ratio | 2.43 |
| P/FCF Ratio | 35.31 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.54, with an EV/FCF ratio of 31.94.
| EV / Earnings | 50.28 |
| EV / Sales | 1.89 |
| EV / EBITDA | 27.54 |
| EV / EBIT | 56.15 |
| EV / FCF | 31.94 |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 0.31.
| Current Ratio | 4.23 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.07 |
| Debt / FCF | 4.72 |
| Interest Coverage | 1.66 |
Financial Efficiency
Return on equity (ROE) is 4.55% and return on invested capital (ROIC) is 2.66%.
| Return on Equity (ROE) | 4.55% |
| Return on Assets (ROA) | 2.26% |
| Return on Capital (ROIC) | 2.66% |
| Revenue Per Employee | 595.51M |
| Profits Per Employee | 22.39M |
| Employee Count | 134 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -39.04% |
| 50-Day Moving Average | 17,520.80 |
| 200-Day Moving Average | 18,372.05 |
| Relative Strength Index (RSI) | 41.97 |
| Average Volume (20 Days) | 79,344 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOREA PHARMA had revenue of KRW 79.80 billion and earned 3.00 billion in profits. Earnings per share was 275.40.
| Revenue | 79.80B |
| Gross Profit | 34.68B |
| Operating Income | 4.47B |
| Pretax Income | 2.12B |
| Net Income | 3.00B |
| EBITDA | 7.26B |
| EBIT | 4.47B |
| Earnings Per Share (EPS) | 275.40 |
Balance Sheet
The company has 38.23 billion in cash and 22.31 billion in debt, giving a net cash position of 15.91 billion or 1,459.17 per share.
| Cash & Cash Equivalents | 38.23B |
| Total Debt | 22.31B |
| Net Cash | 15.91B |
| Net Cash Per Share | 1,459.17 |
| Equity (Book Value) | 71.77B |
| Book Value Per Share | 6,580.57 |
| Working Capital | 58.37B |
Cash Flow
In the last 12 months, operating cash flow was 5.80 billion and capital expenditures -1.07 billion, giving a free cash flow of 4.72 billion.
| Operating Cash Flow | 5.80B |
| Capital Expenditures | -1.07B |
| Free Cash Flow | 4.72B |
| FCF Per Share | 433.01 |
Margins
Gross margin is 43.46%, with operating and profit margins of 5.60% and 3.76%.
| Gross Margin | 43.46% |
| Operating Margin | 5.60% |
| Pretax Margin | 2.66% |
| Profit Margin | 3.76% |
| EBITDA Margin | 9.10% |
| EBIT Margin | 5.60% |
| FCF Margin | 5.92% |
Dividends & Yields
KOREA PHARMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.18% |
| Buyback Yield | -11.10% |
| Shareholder Yield | -11.10% |
| Earnings Yield | 1.80% |
| FCF Yield | 2.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOREA PHARMA has an Altman Z-Score of 5.01.
| Altman Z-Score | 5.01 |
| Piotroski F-Score | n/a |